FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study
AACR Annual Meeting
poster
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
EORTC-NCI-AACR International Conference
FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640
EORTC-NCI-AACR International Conference
Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients
AACR Special Conference: Metabolism and Cancer
